• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics General Medicine Classics

The SPARCL trial: Atorvastatin reduces risk of stroke in patients with recent stroke or transient ischemic attack [Classics Series]

byAndrew Cheung, MD MBA
February 21, 2014
in General Medicine Classics, The Classics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: CC/L. academia

1. In patients with recent stroke or TIA, high-dose atorvastatin significantly reduces the risk of fatal stroke compared to placebo

2. Atorvastatin was also associated with a significant reduction in risk of cardiovascular events

Original Date of Publication: August 10, 2006

Study Rundown: While the trial demonstrated that atorvastatin after stroke or TIA significantly reduced the risk of fatal stroke, there are several criticisms of this trial. One of the main criticisms of the study was the use of industry funding from Pfizer. Moreover, many of the contributors received consulting fees and grant support from various pharmaceutical companies. Lastly, the study was not powered to examine the effect on mortality. Nevertheless, the SPARCL trial has been influential, and has informed the AHA/ASA recommendation for statin therapy in patients with prior stroke and TIA.

In sum, statins should be considered in patients soon after a stroke or transient ischemic attack to reduce the risk of subsequent stroke and cardiovascular events.

Click to read study in NEJM

RELATED REPORTS

Risk of myopathy and myalgia among statin users may be small and clinically insignificant

Polypill strategy reduces the risk of cardiovascular events after a myocardial infarction

Moderate-intensity statin plus ezetimibe is non-inferior to high-intensity statin monotherapy

In-Depth [randomized, controlled study]: Published in NEJM in 2006, the SPARCL trial sought to determine whether atorvastatin would reduce the incidence of stroke or cardiovascular events in patients with recent stroke or transient ischemic attack (TIA). A total of 4,731 patients were randomized to either the treatment group receiving 80 mg of atorvastatin per day or to the placebo group. The primary endpoint was the incidence of fatal or nonfatal stroke. A number of cardiovascular events were also measured as secondary outcomes. Patients were eligible for inclusion if they were 18 years of age and had an ischemic or hemorrhagic stroke or TIA in the 1-6 month period prior to randomization.

Patients were recruited from 205 different centres, and patients were followed for a mean of 4.9 years. Low-density lipoprotein (LDL) cholesterol levels were similar between the two groups at baseline and decreased by 53% in the atorvastatin group while remaining unchanged in the placebo group at one month after randomization. Atorvastatin was associated with a relative risk reduction of 16% for the primary end point of fatal or nonfatal stroke, which was significant according to the prespecified adjusted model. Notably, the atorvastatin group experienced a significant decrease in the risk of fatal strokes, compared to placebo. The statin was also associated with a significant reduction in risk of cardiovascular events, including nonfatal myocardial infarctions, acute coronary events, and revascularization. Interestingly, post-hoc analyses demonstrated that atorvastatin was linked with significantly higher risk of hemorrhagic stroke compared to placebo.

© 2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. Content is produced in accordance with fair use copyrights solely and strictly for the purpose of teaching, news and criticism. No benefit, monetary or otherwise, is realized by any participants or the owner of this domain.

Tags: AtorvastatinsparclSPARCL trial
Previous Post

Maternal folic acid supplementation during early pregnancy associated with lower risk of autism

Next Post

Selumetinib increases the uptake of radioiodine in patients with metastatic thyroid cancer refractory to radioiodine

RelatedReports

Gender conformity influences use of laxatives and muscle-building products
Cardiology

Risk of myopathy and myalgia among statin users may be small and clinically insignificant

September 20, 2022
Nearly Half of All Pediatric Buprenorphine Exposures Result in Hospitalization
Cardiology

Polypill strategy reduces the risk of cardiovascular events after a myocardial infarction

September 15, 2022
2 Minute Medicine Rewind October 12 – 19, 2014
Cardiology

Moderate-intensity statin plus ezetimibe is non-inferior to high-intensity statin monotherapy

August 10, 2022
2 Minute Medicine Rewind October 12 – 19, 2014
Cardiology

Combination-drug therapy and earlier detection recommended to improve outcomes in heterozygous familial hypercholesterolemia

November 16, 2021
Next Post

Selumetinib increases the uptake of radioiodine in patients with metastatic thyroid cancer refractory to radioiodine

Human metapneumovirus is a significant cause of morbidity in children

Post-operative PTSD intervention improves physical outcomes in trauma patients

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Stroke may be associated with sleep disturbances in adults
  • Transcarotid artery revascularization not associated with a significant difference in 30-day risk of stroke, death and myocardial infarction compared to carotid endarterectomy
  • Drinking characteristics in adolescence predict alcohol behaviors in early adulthood
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options